A recent study shows the OCRDs, especially those that are more body-focused, have the potential to emerge or worsen during pregnancy and the postpartum, leading to high levels of comorbid depression and functional impairment.
Despite the unequivocal benefits of folic acid supplementation and recommendations urging all women of reproductive age to take folic acid supplements, preconceptual use of folic acid has not increased substantially.
This task force does not recommend universal, instrument-based screening for perinatal depression because we lack clear evidence that screening improves outcomes.
In a cohort of 351 children exposed to second generation antipsychotic during pregnancy, the risk of major congenital malformations did not differ from a comparison group of non-exposed children.
Cannabis use, as well as use of benzodiazepines and sedative-hypnotic medications, was more common in women with depression.
Second-generation antipsychotic medications associated with high metabolic risk (quetiapine, olanzapine, and clozapine) were associated with increased risk of gestational diabetes; other antipsychotics were not.
Our data regarding prenatal exposure to BZDs and/or z-drugs and risk of neurodevelopmental outcomes is still sparse.
Fetal brain development is altered by elevated maternal distress and has adverse infant social-emotional and cognitive outcomes.
Using a wearable device to track daily symptoms of postpartum depression was viewed as acceptable and clinically useful by participants and clinicians.
More that half of women with bipolar disorder relapsed during pregnancy.
